Tykerb is owned by Novartis.
Tykerb contains Lapatinib Ditosylate.
Tykerb has a total of 1 drug patent out of which 0 drug patents have expired.
Tykerb was authorised for market use on 13 March, 2007.
Tykerb is available in tablet;oral dosage forms.
The generics of Tykerb are possible to be released after 18 September, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8821927||NOVARTIS||Pharmaceutical composition|| |
(6 years from now)
Market Authorisation Date: 13 March, 2007
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic